It is difficult to estimate the prevalence of this CVID subtype, but we can provide the data from an internal dataset based on our experience, observing 0,25% of patients with PID caused by defects in IRF2BP2 (>2000 patients), and approximately 5% of cases with suspected of CVID or primary defects of antibody (165 cases) with LoF mutations in IRF2BP2. Here, IRF2BP2 is linked to pelvic inflammatory disease.